Abstract | Traditionally, scientific research has focused on studying individual events, such as single mutations, gene function, or the effect that mutating one protein has on a biological phenotype. A range of technologies is beginning to provide information that will enable a holistic view of how genomic and epigenetic aberrations in cancer cells can alter the homeostasis of signalling networks within these cells, between cancer cells and the local microenvironment, and at the organ and organism level. This process, termed Systems Biology, needs to be integrated with an iterative approach wherein hypotheses and predictions that arise from modelling are refined and constrained by experimental evaluation. Systems biology approaches will be vital for developing and implementing effective strategies to deliver personalized cancer therapy. Specifically, these approaches will be important to select those patients who are most likely to benefit from targeted therapies and for the development and implementation of rational combinatorial therapies. Systems biology can help to increase therapy efficacy or bypass the emergence of resistance, thus converting the current-often short term-effects of targeted therapies into durable responses, ultimately to improve patient quality of life and provide a cure.
Introduction
For an organism to survive, millions of signals are sent and received every second between cells, tissues, and organs and the external environment, and they are integrated into responses at multiple levels in the body. Robust homeostatic mechanisms must be in place to fine-tune responses and, in particular, allow the organism to deal with potentially toxic environmental perturbations, such as those derived from pathogens, food, air (tobacco smoke, diesel fumes), or drugs. These mechanisms must also be resilient to the effects of spon taneous somatic mutations and the many germline mutations that ultimately alter the biological function of proteins.
In a cancer cell, genomic and epigenetic deregulation results in marked disruption of these homeostatic mecha nisms. 1, 2 Developing an integrated view of the mechanisms by which genomic and epigenetic aberrations disrupt normal cellular function to induce malignant transformation and tumour progression remains a tremendous challenge.
Advances in high-throughput, cost-effective, and tissue-sparing technologies that can analyse tumours at multiple levels, combined with high-speed computing resources, has facilitated a transition in the research paradigm towards an integrated systems biology approach. [3] [4] [5] [6] [7] These new technologies have greatly expanded our ability to develop robust datasets and to integrate the data into an holistic view that is much more than the sum of the parts. Although the traditional research approach is instrumental in the acquisition of basic detailed knowledge of the function of specific genes and proteins, the appreciation of the wider cellular signalling networks between cells, stroma, organs, and the entire organism through an integrated 'systems biology' approach is crucial for the development and implementation of effective anti-cancer strategies. Systems biology is a 'data-driven' science that requires large amounts of high-quality data, crossing multiple scales and concepts in order to build solid and predictive models that can represent the complexity of the cell and its environment. This approach allows an unbiased analysis of the data with the important advantage of being hypothesis-deriving. Several aspect of clinical research can benefit from the use of systems biology, including understanding of (emergent) drug resistance, prediction of effective combination therapies and identification of predictive biomarkers to increase the response rate to targeted treatments.
This Review is an overview of systems biology approaches and resources, focusing on some of the clinical and basic science studies that have benefited from using a systems approach to uncover novel concepts. We also discuss some of the challenges and how this relatively young field can make a positive impact on cancer therapy.
Cancer systems biology
Cancer systems biology represents the application of systems biology approaches to the analysis of how the intracellular networks of normal cells are perturbed during carcinogenesis to develop effective predictive models that can assist scientists and clinicians in the validations of new therapies and drugs. Tumours are characterized by genomic and epigenetic instability that alters the functions of many different molecules and networks in a single cell as well as altering the interactions with the local environment. Cancer systems biology approaches, therefore, are based on the use of computational and mathematical methods to decipher the c omplexity in t umorigenesis as well as cancer heterogeneity.
Projects such as The Cancer Genome Atlas (TCGA), 8 and the International Cancer Genomics Consortium (ICGC), 9 that build on the success of the Human Genome Project, are providing the 'parts list' of cancer; conversely (cancer) systems biology will provide the regulatory logic. 10 Multiple data types are used and integrated, including clinical data. The computational approaches used in cancer systems biology include new mathematical and computational algorithms that reflect the dynamic interplay between experimental biology and the quantitative sciences. A cancer systems biology approach can be applied at different levels, from an individ ual cell to a tissue, a patient with a primary tumour and possible metastases, or to any combination of these situations ( Figure 1 ). This approach can integrate the molecular characteristics of tumours at different levels (DNA, RNA, protein, epigenetic, imaging) and different intervals (seconds versus days) with multidisciplinary analysis. One of the major challenges to its success, besides the challenge posed by the heterogeneity of cancer per se, resides in acquiring high-quality data that describe clinical characteristics, pathology, treatment, and outcomes and integrating the data into robust predictive models.
Modelling approaches involving various aspects of cancer have been successful in predicting the behaviour of cancer cells and tissues in the context of drug response and angiogenesis, and in understanding stem cell heterogeneity. [11] [12] [13] [14] [15] The urgency for the implementation of a successful cancer systems biology programme has been highlighted by the emergence of targeted therapies as cancer treatment. Although targeted therapies have many advantages owing to their ability to specifically target one process, the response rates have not yet fulfilled their early promise and hype. [16] [17] [18] [19] The use of cancer systems biology and integrated network analyses has the potential to support the understanding of the relationship between molecular markers and response to targeted therapies, facilitating the identification of the subgroup of patients most likely to benefit from a particular therapy. It can also facilitate the identification of those combinations of therapies that can result in an increased efficacy or will be able to bypass drug resistance. Resistance to therapy remains the most frequent cause of treatment failure.
A systems analysis of the molecular characteristics of non-responsive or resistant tumours is an exciting opportunity to elucidate mechanisms underlying r esistance and to identify ways to overcome it ( Figure 2) .
Because of the extreme heterogeneity and genomic instability of cancer cells, one of the emerging challenges is to distinguish 'driver' aberrations-which directly alter the behaviour of the tumour, and thus represent potential targets or biomarkers-from 'passenger' aberrations, which do not affect the behaviour of a cancer cell and, therefore, are not effective targets. 20, 21 It is important to emphasize that passenger aberrations can occur within oncogenes, those genes that clearly have a role in cancer pathophysiology, and that different aberrations within oncogenes can have distinct effects on cellular functions and response to targeted therapeutics. Systems-based computational methods have been useful in identifying low frequency mutations in impure and heterogeneous samples, which is related directly to the correct identification of subclonal drivers and, therefore, to our understanding of tumour progression and treatment resistance. 22 Thus, a systems biology approach has the potential to provide the infrastructure to allow a more-efficient d iscrimination between driver and passenger mutations.
Cancer systems biology resources
High-throughput technologies enable comprehensive genomic analyses of mutations, rearrangements, copy number variations, and methylation at the cellular and tissue levels, as well as robust analysis of RNA and microRNA expression data, protein levels and metabolite levels. 3, 20, 21, [23] [24] [25] [26] [27] The data generated by high-throughput technologies and other platforms can be analysed by predict ive mathematical and computational methods. [28] [29] [30] [31] [32] [33] Unfortunately, none of the platforms alone is sufficient to capture the complexity of changes in the genome of a cancer cell or to discriminate optimally between driver and passenger mutations. 34, 35 In addition, all methods generate noise and have their own intrinsic weaknesses, thereby hampering interpretation. Beyond the previously mentioned problem of obtaining high-quality clinical and phenotypic data to be integrated with the 'omics' platforms, a major challenge will be the integration of data across the different platforms. So far, the ability to in tegrate and interpret data across platforms has substantially lagged behind the ability to generate the data; 36 however, integrative genomic studies can provide a new paradigm for the discovery of cancer aberrations and interactions, novel treatments, and resistance mechanisms. Large-scale projects have generated terabytes of omics data that have been curated and made available to the international scientific community (Table 1) . To integrate the data and present them in a way that can be biologically interpreted, 37 novel computational tools and databases of interactions that are accessible to the larger community have been developed (Table 1) . Furthermore, independent of these large-scale projects, many online resources contain annotated high-throughput data, computing and visualization tools, databases of interaction and quantitative biological information (Table 1) . Figure 1 | Application of cancer systems biology to decipher complex interactions in multiple dimensions. This figure shows the complexity of interactions between different molecular networks within the cell. The intracellular machinery must coordinate with surrounding cells and the extracellular microenvironment to achieve homeostasis. Working within the body as a whole, each of these physiologically functional units has to be tightly coupled and regulated. The accumulation of aberrations at the molecular level can decouple any one of these complex interactions and lead to a neoplastic phenotype. The promise of cancer systems biology is the ability to integrate these multi-scale characteristics into cohesive predictive models that can uncover emergent properties to be used in making cancer history. Permission obtained from Visual Art © 2013 The University of Texas MD Anderson Cancer Center. Abbreviations: 1,3BPG, 1,3 biphosphoglyceric acid; 4EBP1, 4E-binding protein 1; ACC, Acetyl-CoA carboxylase; ACL, ATP citrate lyase; AP1, activator protein 1; BAD, bcl2 antagonist of cell death; CBX5, chromobox homolog 5; CREB, cAMP response element-binding protein; FAS, fatty acid synthase; GADP, glyceraldehyde 3-phosphate; GRB2, growth factor receptor-bound protein 2; GRSD, glucose-1-phosphate thymidylyltransferase; GSK3, glycogen synthase kinase 3; LKB1, liver kinase B1; PDH, pyruvate dehydrogenase; PDHK1, pyruvate dehydrogenase kinase 1; PEP, phosphoenolpyruvate; PFK1, phosphofructokinase 1; PKM2, pyruvate kinase M2; RheB, Ras homolog enriched in brain protein; RSK, ribosomal s6 kinase; SGK3, serum-glucocorticoid regulated kinase family member 3; TSC2, tuberous sclerosis protein 2.
The existing systems biology resources contain different types of data that are synergistic and complementary and form the spokes of the cancer systems biology wheel. On the one hand, TCGA, ICGC, and Stand Up to Cancer projects have focused on the collection of tumour samples and on the characterization of their molecular profiles together with data on patient outcomes. On the other hand, CCLE, LINCS, and ICBP projects have focused on obtaining a detailed molecular characterization of the responses of several cancer cell lines to multiple perturbations. Online databases and computing resources contain detailed information on genes, proteins, and molecular interactions as well as online computing software and tools to visualize and analyse large datasets (Table 1) .
Adapting new efforts, such as 'crowd sourcing' to large data analysis, has already provided an exciting and novel way to analyse large systems-level biological data.
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Projects such as the Dialogue for Reverse Engineering Assessments and Methods (DREAM challenge), have made 'big data' , collected through efforts such as the ICBP, available to the international community of c omputational biologists and mathematicians (Table 1) .
Cancer systems biology approaches
In spite of extensive research investigating and uncovering many important aspects of cancer biology, we are still far from an integrated understanding of how the genomic and epigenetic abnormalities that occur in cancer cells mediate their functional consequences. Many groups have assessed large clinical cohorts by measuring one molecular data type (such as gene expression, mutation, single-nucleotide polymorphism) in relation to a measurable outcome to derive correlations between a particular molecular event and disease subtypes. These observational studies are important, but they are insufficient to demonstrate causal ity. Furthermore, the interactions between genes, proteins, and metabolites are coordinated in intracellular and intercellular networks to enable effective interaction with the microenvironment and with all organ systems in our body. The cellular networks that are perturbed in cancer are, in general, the same cellular pathways used by normal cells to perceive and respond to the environment, although not always with the same interactions or spatio-temporal dy namics, owing to the rewiring of the networks as a result of molecular aberrations. In some cases, gene mutations or fusions can result in new functions that are not mediated by the original molecule. These new functions engender ed by genomic aberrations in cancer cells are particularly difficult to deconvolute and integrate into cellular pathways and networks. Because aberrations can occur at various levels and lead to changes in multiple parts of a signalling network, integrating multiple data types from the same tumour becomes necessary in order to derive a more global or systemic understanding of the molecular drivers of that particular cancer.
The TCGA Research Network has developed perhaps the most comprehensive data set encompassing exon and whole-genome sequencing data combined with analysis of DNA copy number, mRNA, microRNA, promoter methylation and protein expression. 8 In each tumour lineage examined, new observations have been reported. For example, the genomic analysis of high-grade serous ovarian cancer in the North American and European populations has revealed the existence of TP53 mutations across virtually all tumours, and the dominant effect of DNA copy number aberrations. Furthermore, this analysis identified specific microRNA, mRNA, or methylation subtypes and the activation of the Notch and FoxM1 pathways as key features of ovarian carcinoma. 25 Similar analyses in breast cancer increased our understanding of previously identified subsets, highlighted the recurrence of mutations in TP53, PIK3CA, and GATA3 genes as well as specific mutations within subtypes-such as PIK3CA in luminal tumours-and led to the identification of new subtypes of breast cancer that were not obvious from previous analyses. 3 In endometrial, colon, and rectal cancer, hypermutated tumours seemed to be a result of micro satellite instability, with a new type of instability driven by POLE gene mutations. 24 Integrated analyses also revealed MYC-directed activation in aggressive colorectal carci noma. 24 The use of this type of analysis in clear-cell renal cell carcinoma, identified cellular oxygen sensing, chromatin remodelling and histone methylation, and metabolic shifts in the tricarboxylic acid (TCA) cycle as key processes in this pathology. 20 Of note, integrated analyses across different cancer types highlighted some striking similarities in terms of molecular characteristics for basal-like breast cancer, high-grade serous ovarian cancer, and serous endometrial cancer. 21 The multiplatform data sets on highly characterized patient samples provide the necessary information for the development of solid and predictive models. However, the importance of an iterative approach wherein hypotheses and predictions arising from the modelling are refined and constrained by experimental evaluation must be emphasized. In addition to such large consortial efforts, several groups have used novel computational methods to integrate different data types to elicit novel principles. Carro et al., 11 using gene expression and network approaches, identified key transcriptional factors, such as CEBP and STAT3, as master regulators of the mesenchymal transformation in glioblastoma. Importantly, they demonstrated that the expression of these transcription factors could predict poor clinical outcome. 11 In another approach the integration of protein and phosphoproteomic interactions with transcription factor-DNA binding data led to the discovery of novel features of cellular responses to stress and growth factors. 12, 29 Similarly, systems-level analyses of proteomic and metabolomic data revealed novel regulatory functions between these two important cellular networks that would not have been achieved otherwise. 40 Furthermore, the integration, through network analysis, of mRNA expression data with proteomic, phosphoproteomic and clinical outcomes data, enabled the identification of key regulators of EGFR signal ling and correlated these events with patient survival. 41 Whole-genome sequencing and proteomics were also used to identify new driver genes in endo metrial cancer and to identify a novel functional association between ARID1A and PI3K pathway activity.
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Systems approaches for tissue complexity In any tissue in the body, there is extensive interaction between cells within the organ and the microenvironment, giving rise to an additional layer of complexity 43 However, an understanding of the mechanisms underlying these disparate processes remains elusive. This complex functionality may in fact only be solved via a systems biology approach. The molecular aberrations in cancer can significantly alter the normal dynamics of (neo)vascularization and hypoxia response. 44 Furthermore, the role of the microenvironment in tumour dormancy and evading therapeutic interventions that allows oestrogen receptor-positive breast cancer to recur years later remains elusive.
Owing to the complexity of the tumour microenvironment interactions, many other aspects of cancer biology have not been explained by traditional scientific approaches and can benefit from the integrated analysis supported by systems biology. 2, 45, 46 Imaging of cells and their interactions with the extracellular environment can provide the high-quality data needed for the development of predictive models. To distinguish a stromal signature from a tumour signature and to understand the influence of different (metastatic) microenvironments, or how stromal expression changes can influence tumour progression, several strategies have been used. An extensive analysis of gene-expression patterns in primary and metastatic tumours, applying novel statistical analytical methods, led to the discovery of genes that were reprogrammed in brain metastases, but not in other metastatic sites. 47 This reprogramming event was a function of the local microenvironment, likely regulated by promoter methy lation. 47 Finak et al. 48 purified tumour stromal cells by laser capture microdissection, compared geneexpression data of the tumour stroma to healthy stroma, and developed a stromal signature with clear prognostic impact independ ent of tumour subtypes. Thus, using systems-based methods, several groups have shown that the stroma has an important interplay with the tumour and has clear effects on disease progression and possibly also on effective treatment options. Developing computational models to fit the complex dynamics of the cellular microenvironment can provide potential hypoth eses to be tested experimentally and aid in the interpretation of the results. This iterative approach provides the basis for a truly integrative model ling and experimental platform. Several experimental approaches are well adapted to feed data for this high-complexity integrative platform. Threedimensional culture systems provide a potential approach to mimic the in vivo situation more realistically. Multiple articles have shown that in contrast to 2D-culture, cells grown in 3D respond differently to chemotherapy and radiotherapy, 49, 50 and also have markedly different geneexpression patterns related to the extracellular matrix and cell adhesion. 51 Moreover, microfluidic systems, in which tissues and even multiple different cell lineages can be studied in relatively high-throughput (micro)models, provide another experimental approach to support the modelling of the interactions between the tumour and microenvironment. [52] [53] [54] [55] [56] These in vitro approaches, therefore, have the potential to provide tractable experimental systems to develop hypotheses to test in vivo and also to experimentally test mathematical models developed from in vivo studies. Integrating in vitro and in vivo modelling approaches can have a major role in understanding how spatial orientation and interactions with the m icroenvironment can affect diverse tumour behaviour.
Response to targeted treatment and tumour progression are intrinsically linked to immunological pathways. At a single platform level, the complex interplay from the multitude of players cannot be completely captured. Kristensen et al. 57 used a pathway recognition algorithm and multi level data from TCGA to show that tumours can be stratified according to their immune signatures. This stratifi cation is shown to be relevant for patient survival and targeted treatment response. 57 Of note, multiscale analy sis showed that the tumour can recreate its immune environment throughout cancer progression, highlighting the importance of understanding the r elationship between the tumour and the microenvironment. 58 Several investigators have developed modelling approaches to study the relationship between intracellular pathways and the behaviour of cells at the tissue level. 59 Recently, some researchers modelled Myc and p53 pathways during the proliferation of lymphoma cells in the context of surrounding tissue, growth factors, and angiogenesis. 60 In addition, models that consider the effect of cell division rates as well as interactions between cancer cells and the microenvironment predicted that the order in which targeted and chemotherapy approaches are delivered is important as the proliferation rates and migration capabilities of different cell types could alter the tissue level response to therapy. 61 Critically, these models will help to predict how effects at small intervals within the cell relate to long-term effects observed at the tissue or whole body level. Mathematical models of the spatiotemporal heterogeneity of the extracellular matrix have provided unexpected insights into how, for example, the urokinase plasminogen activation system has an effect on cell invasion. 62 The aforementioned studies primarily used omics data derived from analyses of tumour lysates without the consideration of spatial orientation, although one of the key aspects of the tumour microenvironment is spatial constraints. To incorporate spatial information, imaging of tumour cells and their environment is of paramount importance, particularly in the context of angiogenesis. The differential imaging of blood vessels and cell types using fluorescent probes as well as intra vital imaging of tumours in animal models and cell cultures are techniques that provide the data necessary to develop 'tissue-level' computational models that can incorporate all these facets. For example, two predictive models for angiogenesis and cell-cell interactions have been developed, by incorporating imaging data, in order to study in vivo aspects of the tumour biology and drug response, respectively. 72, 73 Furthermore, Haeno et al. 63 used a dissemi nation dynamics model (including well-annotated patient data) to predict the type and sequential order of treatments most likely to benefit patients with pancreatic cancer. This model can have important clinical implications for this disease that has a notoriously poor prognosis. Importantly, Kim and colleagues 64 highlighted the applicability and individual benefits of different types of modelling in combination with in vitro and patient data to study spatio-temporal drug distribution within the tumour to optimize drug selection and delivery.
Systems approaches for cell heterogeneity Cancer stem-like cells, also known as tumour-initiating cells, have been intensely studied in recent years. These studies have been driven in part by the discovery that the presence of cancer stem-like cells likely contributes to drug resistance and poor outcome. 65, 66 Interestingly, characteristics previously attributed to epithelial-mesenchymal trans ition (EMT), including EMT markers and mesenchymal morphology, can contribute to or be associated with a cancer stem cell-like state and drug resistance. 67 The ability to transition in and out of an EMT-like state is critical for a cell to initiate and complete the metastatic process. 68, 69 Systems-based analysis of prostate cancer identified a molecular signature associated with patient outcome. 70 Moreover, the results from this study highlighted an extensive plasticity of basal cells, supporting a model in which cells of origin can generate distinct m olecular subtypes of prostate cancer. 70 Different models of the spatio-temporal dynamics of stem cells in both healthy cells and tumour cells have been published to evaluate normal olfactory epithelium, 71 bowel crypts, 72 and solid tumours 73 in an attempt to understand the regulatory strategies of cell renewal. These models give rise to the hypothesis that stem cells are not cell types as such, but rather a cell with a particular behaviour imposed by feedback mechanisms. Such mechanisms are still in place in tumours, although they are susceptible to perturbations, including those induced by treatment. Changes in tumour size can alter cell proliferation and death by disturbing the feedback mechanisms and shift the balance towards cell renewal. These models could help in predict ing which approaches might successfully shrink the tumour and benefit patients. 73 Intratumoural and intertumoural heterogeneity contri bute to patient prognosis and predicts response to therapy. 69, 74 Intratumoural heterogeneity may represent the greatest challenge to deliver effective personalized cancer therapy. Tyson et al. 75 developed novel automated tools to capture and quantitate multiplexed imaging features to develop predictive models of the heterogeneity of response of individual cells to perturbations and were able to show heterogeneous cell fates upon exposure to anti-proliferative drugs. In another study, Yankeelov et al., 76 used quantitative tumour imaging methods and developed a model of interactions between cancer cells, stroma and immune cells, vascularisation and the extracellular matrix, that was able to predict treatment response and tumour progression. These modelling approaches have been very useful in enabling us to understand cellular heterogeneity and response to perturbations, and lay the foundation of how we can use such information to develop novel methods to treat tumours that are inherently heterogeneous.
Systems approaches for targeted therapy
One of the continual challenges in the use of targeted therapy is the low response rates observed in the clinical setting. [16] [17] [18] [19] In many cancer systems biology efforts, novel computational and mathematical methods are used to integrate and analyse patients' molecular data to identify optimal markers and targets. Recent efforts focusing on colorectal and liver cancers have integrated whole-genome expression data with patient's outcomes to classify patients and their therapy responses according to gene-expression patterns. 77 Using unbiased analysis of these datasets, the investigators identified specific expression patterns and pathways that were associated to specific mutations in the tumour, and those patterns responsible for altering drug response in the cancer cells. 77 Furthermore, extensive computational analysis of a large metabolic network revealed key regulatory nodes, such as oxidative phosphorylation, glycolysis and citric acid cycle that could serve as optimal targets for therapy. 78, 79 Several groups have also integrated phosphoproteomic time-course data of cell line responses to growth factors and perturbations in epithelial tumours, developing predictive data-driven models to identify rational targets and combinations of drugs for effective therapy. 13, 33, 80, 81 In diseases with limited therapeutic options (such as pancreatic cancer) an extensive systems biology approach integrating gene-expression data from primary pancreatic ductal adenocarcinomas and from human or murine pancreatic adenocarcinoma cell lines, revealed novel classifiers, predicted potential subtype-specifi c therapies, and identified non-responders. 82 Beyond pancreatic cancer, an area of intense research in terms of systems biology has been breast cancer. Much work has in fact focused on molecular phenotypes and drug responses in breast cancer. These efforts used several systems-level approaches, including large 'omics' data acquisition, analysis of patients and responses to clinically approved drugs as well as large panels of cell line-based assays. 26, 40, [83] [84] [85] [86] [87] Computational modelling and analysis of perturbation screens using non-coding RNA have also proven useful in defining network topologies and predict ing combinations of targets based on mechanistic f unctions of subnetworks. 7, [88] [89] [90] Approaches for drug resistance As mentioned before, drug resistance is one of the major challenges to effective cancer treatments. Integration of thousands of omics data points acquired from sensitive and resistant tumours into a systems-based therapeutic strategy has been shown to be a powerful tool for fighting resistance. 77, 91 For example, models of dynamic changes in signalling networks of receptor tyrosine kinases (RTK) families have facilitated the classification of RTKs and their network activation and led to the identification of points of intervention to delay or overcome drug resistance. 80, 92 Furthermore, Komurov et al., 93 used a novel network-based analysis of gene expression and proteomics coupled to HER2-positive patient survival data, and showed that in breast tumours with acquired resistance to lapatinib, the drug was still able to block EGFR/HER2 signalling. However, upregulation of glucose metabolism, unfolded protein response, and endoplasmic reticulum (ER) stress pathways mitigated the ability of lapatinib to induce cell death, suggesting that coordinated targeting of metabolic networks and signalling networks has the potential to improve patient outcomes. 93, 94 Beckman et al. 95 illustrated that the potential effects on drug response and resistance acquisition induced by single cell hetero geneity and cellu lar dynamics can be mathematically modeled and, therefore, should be included in personalized treatment strategies. They demonstrated that a strategy targeting all cancer subpopulations including the precursors of resistant clones, rather than treatment targeting the clone predominantly present, which therefore initially leads to the largest reduction in tumour size, may be more effective. As such, counterintuitive strategies may be of advantage for patient outcome. Lastly, integrating patient data with murine models has proven a powerful systems approach to identify mechanisms to overcome resistance to androgen therapy in prostate cancers. 96 All these different studies highlight how using systems biology approaches can improve targeted therapy and help to o vercome drug resistance.
With the aim of improving effective combinatorial drug prediction in cancer, mathematical modelling combined with high-density time-dependent measurements showed that modulation of oncogenic pathways through sequential application of drug combinations is possible and can render cancer cells much more susceptible to the drugs, thus significantly increasing the efficacy of treatment. 97 Context-specific metabolic modelling algorithms demonstrated feasibility in predicting drug targets and phenotypic tumour response, including off-target effects, making this an effective systems approach for the develop ment of new (combinatorial) drugs therapy. 98 For example, STK38 (serine-threonine kinase 38) was identified as an upstream regulator of MYC activity through a model of network dynamics (the modulator inference by network dynamics [MINDy] algorithm) aimed at predicting transcription factor modulators. Experimental manipulation of STK38 demonstrated inhibition of tumour growth in MYC-dependent tumours in vivo; and thus a potential novel means to target these tumours. 99 Cancer systems biology has made an impact on drug discovery and development from the identification of targets up to the clinical trial stage. Computational analysis of the HER family network has revealed HER3 as a key node of ligand-induced HER2 activation. 100 These results facilitated the engineering of a bispecific HER3 antibody, MM-111, that inhibits ligand-induced receptor activation in HER2-overexpressed tumours and, as such, bypasses the tumour HER3 escape route that is often activated in drug resistance. 101 Computational modelling-together with pharmacodynamic and tumour growth algorithms-aimed to identify optimal drug combinations with MM-111 to prevent drug resistance. 102 Of note, the MM-111 antibody, a drug that would not likely have been developed without a systems biology approach, is currently in clinical development. 102 The examples described in this Review highlight the potential of combining multiscale high-throughput data analysis with mathematical modelling to identify novel and sometimes unexpected principles. Importantly, a number of these models are being used to develop s election approaches for implementation into clinical trials.
Data sharing
Although large-scale collections of data are inherently associated with the risk of multiple errors, making these data sets available to the cancer research community and the public, facilitates the recognition of these possible errors. [103] [104] [105] Bilal et al. 103 have proposed competitionbased modelling using large datasets with omics and clinical information to improve survival predictions among patients with breast cancer. The fact that the data sets are available to the public, allows the models to evolve through interaction with the community and prevents the so-called 'self-assessment trap' , in which model building and testing are carried out within the same group with the risk of reporting results that may be too favourable. A different crowdsourcing research study focused on developing prognostic models for breast cancer using genome-scale data (gene expression, copy number analysis, and clinical variables), and showed the approach to be capable of generating prognostic models of at least equal quality to previously reported studies, 106 and consistent across multiple independent evalu ations.
38,39 Much as there have been different experimental approaches to understand cancer, there have also been many different modeling approaches that have been developed. The modeling approaches use different algorithms and these are largely dependent on the type of data that has been available and the questions that are being addressed.
Conclusions
The era in which cancer was treated solely according to the organ of origin is coming to an end, leaving space for a greater understanding of the complex interactions between the genomic aberrations present in tumour cells, the intrinsic gene-expression patterns of the tissue of origin, and the tumour microenvironment (Figure 2 ). Cancer systems biology has the potential to usher in an era in which the effects of molecular aberrations and interactions within networks are integrated with molecular knowledge and pharmacogenomics. Improvements in our ability to image and measure quantitatively spatial localization of network activities and incorporate spatiotemporal information acquired in patients using 'omics' data and computational analysis are providing the right platform for systems biology to impact on patient outcomes. Cancer systems biology approaches can improve our understanding of how tumour heterogeneity, neovascularization, immune response, and changes in the tumour and its microenvironment over time and in response to therapeutic interventions contribute to treatment response. Cancer systems biology is a young field and clinical studies have not yet been reported based on systems approaches, nevertheless systems biology has already shown a great potential and it is clear that it will have a major role in the further development of personalized therapy. In our opinion, the greatest opportunity for cancer systems biology in the near future is to elicit emergent mechanisms of resistance and identify rational combi nation approaches to prevent or bypass drug resistance. It will also be important to incorporate side effects and toxicities in the models. In this way, systems approaches will contribute to the development of the next generation of clinical trials and cancer therapy.
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A search for original articles was performed in MEDLINE and PubMed, with the search terms "integrative/systematic analysis", "computational/ mathematical modeling", "multidimensional networks", "genetic dynamics", "cellular heterogeneity", alone and in combination; with a strong emphasis on literature published in the past 3 years. All articles identified were English-language, full-text papers. We also searched the reference lists of identified articles for further relevant papers.
